image credit- shutterstock
Japan-based pharma firm Kyowa Kirin has announced plans to create a state-of-the-art research hub, to further improve its capabilities in drug discovery. The plan is to integrate two existing sites, the Fuji Site and Tokyo Research Park, into a new integrated research hub at Yokohama Business Park.
Specific conditions and the implementation schedule will be determined through further reviews with relevant stakeholders. Following the potential launch of the new research hub, Kyowa Kirin is considering the closure of both the Fuji Site and Tokyo Research Park.
As drug discovery environments become increasingly challenging due to the emergence of new modalities, advances in AI, and growing technological complexity, Kyowa Kirin is advancing initiatives to further enhance the very way its research and development activities are conducted, guided by its mission to deliver life-changing value to patients.
Specifically, the company aims to create a research environment in which Drug Discovery, Translational Research (TR), and Chemistry, Manufacturing and Controls (CMC) engage in ongoing, day-to-day discussions from the early stages of research.
By strengthening collaboration across these functions, Kyowa Kirin seeks to enable research design and faster decision-making with downstream development and manufacturing in mind. Through these efforts, the company aims to increase both the speed and quality of research outcomes and enhance the overall competitiveness of its research and development capabilities.
The new integrated research hub represents one of multiple measures Kyowa Kirin is pursuing to enhance its drug discovery capabilities, building on the important role both research parks have played in Kyowa Kirin's history of research and drug discovery. The new hub will build on the strengths, expertise, and research culture developed at these sites, while exploring a research framework suited to the next era.
